Cell>Point Biotechnology Company

Cell>Point is a clinical-stage biopharmaceutical company specializing in the development of molecular imaging and theranostic agents for oncology and cardiology. The company's core technology is based on a proprietary ethylenedicysteine (EC) drug delivery platform, which allows for the stable labeling of various ligands with radioisotopes like Technetium-99m for diagnostic imaging and Rhenium-188 for therapy. Its lead product, OncoTrace, is a technetium-labeled glucosamine analog currently in Phase 3 trials, designed to provide a cost-effective and widely accessible alternative to FDG-PET for cancer staging. By utilizing SPECT/CT imaging, Cell>Point aims to bring high-resolution molecular diagnostics to community hospitals that lack expensive PET infrastructure. The company is also expanding its pipeline to include agents for myocardial viability and targeted radiotherapeutic treatments.